Nurix Therapeutics, Inc.
NRIX
$10.55
$0.313.03%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.26% | -12.37% | -31.84% | -60.58% | 30.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.26% | -12.37% | -31.84% | -60.58% | 30.74% |
| Cost of Revenue | 39.31% | 35.22% | 15.93% | 6.90% | 9.14% |
| Gross Profit | -53.23% | -56.10% | -45.95% | -144.12% | -0.87% |
| SG&A Expenses | -1.23% | -0.58% | 10.31% | 0.27% | 20.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.57% | 28.84% | 14.91% | 5.56% | 11.08% |
| Operating Income | -39.02% | -42.62% | -36.49% | -81.36% | -5.28% |
| Income Before Tax | -36.02% | -39.53% | -32.16% | -83.12% | -1.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.73% | -39.55% | -32.38% | -83.49% | -1.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.73% | -39.55% | -32.38% | -83.49% | -1.93% |
| EBIT | -39.02% | -42.62% | -36.49% | -81.36% | -5.28% |
| EBITDA | -40.16% | -41.54% | -37.19% | -85.81% | -4.79% |
| EPS Basic | 10.82% | 2.70% | 1.06% | -59.61% | -0.31% |
| Normalized Basic EPS | 10.62% | 2.71% | 1.25% | -59.30% | -0.08% |
| EPS Diluted | 10.82% | 2.70% | 1.06% | -59.61% | -0.31% |
| Normalized Diluted EPS | 10.62% | 2.71% | 1.25% | -59.30% | -0.08% |
| Average Basic Shares Outstanding | 52.20% | 43.42% | 33.81% | 14.96% | 1.62% |
| Average Diluted Shares Outstanding | 52.20% | 43.42% | 33.81% | 14.96% | 1.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |